DISCLAIMER

DISCLAIMER: The author is not a registered stockbroker nor a registered advisor and does not give investment advice. His comments are an expression of opinion only and should not be construed in any manner whatsoever as recommendations to buy or sell a stock, option, future, bond, commodity, index or any other financial instrument at any time. While he believes his statements to be true, they always depend on the reliability of his own credible sources. The author recommends that you consult with a qualified investment advisor, one licensed by appropriate regulatory agencies in your legal jurisdiction, before making any investment decisions, and that you confirm the facts on your own before making important investment commitments.
Showing posts with label Becton Dickinson. Show all posts
Showing posts with label Becton Dickinson. Show all posts

Tuesday, June 1, 2010

Why is consumer economy is dead even 1 year after the financial crisis

One year after the near collapse of the global financial system, this much is clear: The financial world as we knew it is over, and something new is rising from its ashes.

Historians will look to September 2008 as a watershed for the U.S. economy.

On Sept. 7, the government seized mortgage titans Fannie Mae and Freddie Mac. Eight days later, investment bank Lehman Brothers filed for bankruptcy, sparking a global financial panic that threatened to topple blue-chip financial institutions around the world. In the several months that followed, governments from Washington to Beijing responded with unprecedented intervention into financial markets and across their economies, seeking to stop the wreckage and stem the damage.

One year later, the easy-money system that financed the boom era from the 1980s until a year ago is smashed. Once-ravenous U.S. consumers are saving money and paying down debt. Banks are building reserves and hoarding cash. And governments are fashioning a new global financial order.

Congress and the Obama administration have lost faith in self-regulated markets. Together, they're writing the most sweeping new regulations over finance since the Great Depression. And in this ever-more-connected global economy, Washington is working with its partners through the G-20 group of nations to develop worldwide rules to govern finance.

"Our objective is to design an economic framework where we're going to have a more balanced pattern of growth globally, less reliant on a buildup of unsustainable borrowing . . . and not just here, but around the world," said Treasury Secretary Timothy Geithner.

The first faint signs that the U.S. economy may be clawing its way back from the worst recession since the Great Depression are only now starting to appear, a year after the panic began. Similar indications are sprouting in Europe, China and Japan.

Still, economists concur that a quarter-century of economic growth fueled by cheap credit is over. Many analysts also think that an extended period of slow job growth and suppressed wage growth will keep consumers — and the businesses that sell to them — in the dumps for years.

"Those things are likely to be subpar for a long period of time," said Martin Regalia, the chief economist for the U.S. Chamber of Commerce. "I think it means that we probably see potential rates of growth that are in the 2-2.5 (percent) range, or maybe . . . 1.8-1.9 (percent)." A growth rate of 3 percent to 3.5 percent is considered average.

The unemployment rate rose to 9.7 percent in August and is expected to peak above 10 percent in the months ahead. It's already there in at least 15 states. Regalia thinks that it could be five years before the U.S. economy generates enough jobs to overcome those lost and to employ the new workers entering the labor force.

All this is likely to keep consumers on the sidelines.

"I think this financial panic and Great Recession is an inflection point for the financial system and the economy," said Mark Zandi, the chief economist for forecaster Moody's Economy.com. "It means much less risk-taking, at least for a number of years to come — a decade or two. That will be evident in less credit and more costly credit. If you are a household or a business, it will cost you more, and it will be more difficult to get that credit."

The numbers bear him out. The Fed's most recent release of credit data showed that consumer credit decreased at an annual rate of 5.2 percent from April to June, after falling by a 3.6 percent annual rate from January to March. Revolving lines of credit, which include credit cards, fell by an annualized 8.9 percent in the first quarter, followed by an 8.2 percent drop in the second quarter.

That's a sea change. For much of the past two decades, strong U.S. growth has come largely through expanding credit. The global economy fed off this trend.

China became a manufacturing hub by selling attractively priced exports to U.S. consumers who were living beyond their means. China's Asian neighbors sent it components for final assembly; Africa and Latin America sold China their raw materials. All fed off U.S. consumers' bottomless appetite for more, bought on credit.

"That's over. Consumers can do their part — spend at a rate consistent with their income growth, but not much beyond that," Zandi said.

If U.S. consumers no longer drive the global economy, then consumers in big emerging economies such as China and Brazil will have to take up some of the slack. Trade among nations will take on greater importance.

In the emerging "new normal," U.S. companies will have to be more competitive. They must sell into big developing markets; yet as the recent Cash for Clunkers effort underscored, the competitive hurdles are high: Foreign-owned automakers, led by Toyota, reaped the most benefit from the U.S. tax breaks for new car purchases, not GM and Chrysler.

Need a loan? Tough luck: Many U.S. banks are in no condition to lend. Around 416 banks are now on a "problem list" and at risk of insolvency. Regulators already have shuttered 81 banks and thrifts this year.

The Federal Deposit Insurance Corp. reported on Aug. 27 that rising loan losses are depleting bank capital. The ratio of bank reserves to bad loans was 63.5 percent from April to June, the lowest it's been since the savings-and-loan crisis in 1991.

For all that, the U.S. economy does seem to be rising off its sickbed. The latest manufacturing data for August point to a return to growth, and home sales are rising. Indeed, there are many encouraging signs emerging in the global economy.

It's all growth from a low starting point, however, and many economists think that there'll be a lower baseline for U.S. and global growth if the new financial order means less risk-taking by lenders and less indebtedness by companies and consumers.

That seems evident now in the U.S. personal savings rate. It fell steadily from 9.59 percent in the 1970s to 2.68 percent in the easy-money era from 2000 to 2008; from 2005 to 2007, it averaged 1.83 percent.

Today, that trend is in reverse. From April to June, Americans' personal savings rate was 5 percent, and it could go higher if the unemployment rate keeps rising. Almost 15 million Americans are unemployed — and countless others are underemployed or uncertain about their job security, so they're spending less and saving more.

A few years ago, banks fell all over themselves to offer cheap home equity loans and lines of consumer credit. No more. Even billions in government bailout dollars to spur lending haven't changed that.

"The strategy that was stated at the beginning of the year — which is that you would sustain the banking system in order that it would resume lending — hasn't worked, and it isn't going to work," said James K. Galbraith, an economist at the University of Texas at Austin.

Over the course of 2008, the nation's five largest banks reduced their consumer loans by 79 percent, real estate loans by 66 percent and commercial loans by 19 percent, according to FDIC data. A wide range of credit measures, including recent FDIC data, show that lending remains depressed.

Why? The foundation of U.S. credit expansion for the past 20 years is in ruin. Since the 1980s, banks haven't kept loans on their balance sheets; instead, they sold them into a secondary market, where they were pooled for sale to investors as securities. The process, called securitization, fueled a rapid expansion of credit to consumers and businesses. By passing their loans on to investors, banks were freed to lend more.

Today, securitization is all but dead. Investors have little appetite for risky securities. Few buyers want a security based on pools of mortgages, car loans, student loans and the like.

"The basis of revival of the system along the line of what previously existed doesn't exist. The foundation that was supposed to be there for the revival (of the economy) . . . got washed away," Galbraith said.

Unless and until securitization rebounds, it will be hard for banks to resume robust lending because they're stuck with loans on their books.

"We've just been scared," said Robert C. Pozen, the chairman of Boston-based MFS Investment Management. He thinks that the freeze in securitization reflects a lack of trust in Wall Street and its products and remains a huge obstacle to the resumption of lending that's vital to an economic recovery.

Enter the Federal Reserve. It now props up the secondary market for pooled loans that are vital to the functioning of the U.S. financial system. The Fed is lending money to investors who're willing to buy the safest pools of loans, called asset-backed securities.

Through Sept. 3, the Fed had funded purchases of $817.6 billion in mortgage-backed securities. These securities were pooled mostly by mortgage finance giants Fannie Mae, Freddie Mac and Ginnie Mae. In recent months, the Fed also has moved aggressively to lend for purchase of pools of other consumer-based loans.

Today, there's little private-sector demand for new loan-based securities; government is virtually the only game in town. That's why on Aug. 17, the Fed announced that it would extend its program to finance the purchase of pools of loans until mid-2010. That suggests there's still a long way to go before a functioning securitization market — the backbone of consumer lending — returns to a semblance of normalcy.

BD Board Declares Dividend (Part of Warren Buffett Portfolio)

The Board of Directors of BD (Becton, Dickinson and Company) (NYSE:BDX) has declared a quarterly dividend of 37 cents per common share, payable on June 30, 2010 to holders of record on June 9, 2010. The indicated annual dividend rate is $1.48 per share.

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people’s health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD’s capabilities are instrumental in combating many of the world’s most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.

Just pay $1 to Claim $4,276 Internet System from world’s #1 internet wealth expert for one month. Limited Offer!
Over 55,000 satisfied customers worldwide!


Friday, April 30, 2010

Becton, Dickinson posts $300 million in Q2 profits

Net income grew 14 percent to nearly $300 million at Becton, Dickinson & Co. (NYSE:BDX) during the company's fiscal second quarter that ended March 31.

The $1.24-a-share profit topped consensus analyst opinion by a penny, although revenues fell just short of the $1.85 billion Wall Street estimate for the quarter. BD officials said they now anticipate revenues for the fiscal year ending in September to rise 6 percent to around $7.59 billion — or about $70 million below the company's previous forecast due to currency fluctuations.

The BD executives also estimated that changes in Medicare Part D reimbursements enacted under federal legislation could trim reported earnings over the second half of fiscal 2010 by roughly $9.5 million, or about 4 cents per share.

Overall, the Franklin Lakes, N.J.-based medical device manufacturer said it generated $297.7 million in net income on $1.88 billion in revenues during the January-to-March fiscal period. That compares with a $261.2 million profit during the year-ago quarter on sales of $1.73 billion.

The company enjoyed strong performance within its BD Medical segment by diabetes care and pharmaceutical system products. It also saw gains with diagnostic kits used to detect cancer and sexually transmitted diseases, as well as growth in selected markets with labware used in cell analysis and discovery.

On the downside, a relatively mild flu season this past winter — including limited outbreaks of the Swine Flu virus — undercut sales of test kits, the company said.

Free Book "Make Real Money on the Internet" from world’s #1 internet wealth advocate Absolutely free!

Claim Your Free Copy!

Thursday, February 11, 2010

update: Becton, Dickinson & Co

Becton, Dickinson & Co. said Wednesday that a recently recalled part that hospitals use to deliver fluids intravenously wasn't responsible for a death it was investigating for possible links to the device.

The company's investigation also revealed that a serious injury linked to the Q-Syte Luer Access components was unfounded and the patient didn't experience any harm, said Becton spokeswoman Colleen White.

The Q-Syte components are part of a needle-less IV system that Becton has sold since late 2003. The systems are used to pump medicine, fluids or blood products into patients, or to withdraw blood.

Becton, of Franklin Lakes, N.J., has recalled 7.8 million of the parts because of a manufacturing defect that the company says affected production of certain lots from November 2008 to November 2009.

The company recalled some of the parts in October and more this week. It said it has fixed the defect and taken steps to prevent its recurrence.

Free Book "Make Real Money on the Internet" from world’s #1 internet wealth advocate for making money online! Absolutely free.. Get a copy!

Wednesday, February 3, 2010

Becton Dickinson Board Declares Dividend

The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of 37 cents per common share, payable on March 31, 2010 to holders of record on March 10, 2010. The indicated annual dividend rate is $1.48 per share.

Work from Home for financial freedom!!


Becton Beats, Bumps Estimates

Becton recently reported first quarter fiscal 2010 results. Earnings per share of $1.30 easily beats the Zacks Consensus Estimate of $1.20 and the year-ago earnings of $1.26. The company also reported an expansion in its top-line with growth across all major business segments.

BD Medical revenues increased 16% year over year to $1.019 billion. Growth can be attributed to higher sales of Medical Surgical, Pharmaceutical Systems and Diabetes Care products.

BD Diagnostics revenues increased 10% year over year to $595 million. Growth was primarily due to higher demand for the company’s safety-engineered devices and infectious disease testing systems.

BD Biosciences revenues were approximately flat year over year at $303 million. Becton’s capital funding constraints negatively impacted sales of clinical and research instruments in this business category.

Becton has also raised its sales and earnings per share guidance for full fiscal 2010. For the year, Becton now expects revenues to increase roughly 7% year over year, compared to the previous guidance of 6%. Earnings per share should increase approximately 2%−4% year over year to $5.05−$5.15. Becton’s previous guidance was an increase of 1%−3% year over year in earnings per share.

Becton, Dickinson and Company develops, manufactures and markets medical devices, supplies, laboratory equipment and diagnostic products globally. The company is a world leader in safety needle products. Becton competes with players like Baxter International Inc. , Johnson & Johnson and Abbott Laboratories

Work From Home
Learn from world's #1 internet wealth advocate for making money on line, Stephen Pierce.

Friday, January 22, 2010

Piper Jaffray Downgrades Becton, Dickinson (BDX) to Neutral

Piper Jaffray downgrades Becton, Dickinson (NYSE: BDX) from Overweight to Neutral. Price target $78.

Piper analyst says, "Overall, our favorable fundamental thesis on Becton Dickinson remains intact, however, with BDX shares trading very close to our 12-month price target we believe it is fully valued and warrants a Neutral rating. We anticipate BD to benefit from traction with recently launched products (e.g. Nexiva catheter, Viper XTR, etc.), pipeline products (e.g. diabetic pen needles, BD MAX) and favorable macro trends (e.g. international safety adoption, stimulus) and would view pullbacks into the upper $60's as an attractive entry point...We would note a favorable foreign exchange impact in 1Q09 benefitted gross margin by 220 bpts. We anticipate flattish operating expenses yoy (down 20 bpts yoy to 29.1% of revenue), which combined with the gross margin decrease translates into EPS of $1.20 (Street consensus $1.21)."

Becton, Dickinson and Company (BD) is a medical technology company engaged principally in the development, manufacture and sale of a range of medical supplies, devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.

Work From Home: Learn from world's #1 internet wealth advocate for making money on line with just $1

Sunday, January 10, 2010

Becton Dickinson Applauds PEPFAR's Broadened Emphasis on Strengthening Health Systems

BD (Becton, Dickinson and Company) a leading global medical technology company, has praised the recent announcement that the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) will increase its emphasis over the next five years on strengthening health systems in developing countries.

BD currently collaborates with PEPFAR on three separate initiatives that promote the long-term sustainability of healthcare delivery throughout sub-Saharan Africa. The programs focus on strengthening laboratory systems, protecting healthcare workers, and improving blood collection practices in the region.

On December 1, 2009, World AIDS Day, Ambassador Eric Goosby, the U.S. Global AIDS Coordinator, announced that the United States would launch a new five-year strategy that will move PEPFAR "from an emergency response to one of durable health systems that are designed to serve the medical needs of people with HIV/AIDS and the communities where they live," as reported in an article posted on the U.S. State Department's America.gov website.

"We're going to begin transitioning from an emergency response to a sustainable one through greater engagement with and capacity building of governments," said Ambassador Goosby.

Similarly, on November 30, 2009, Secretary of State Hillary Rodham Clinton said that PEPFAR's second five-year phase will witness a "transitioning from emergency response to sustainable health systems that help meet the broad medical needs of people with HIV and the communities in which they live."

BD's three public-private collaborations with PEPFAR are focused on different areas of health system strengthening. The laboratory strengthening program involves extensive training of laboratory technicians in quality control systems and specific testing procedures for diagnosing and monitoring HIV/AIDS and tuberculosis. The Wellness Center initiative, pursued in collaboration with the International Council of Nurses, provides essential services to health workers and their families including discreet HIV testing and treatment. Most recently, BD and PEPFAR announced the launch of a third program focused on safe blood sampling and handling practices. It is anticipated that as many as 10,000 health workers will be trained in this program.

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.

Claim Your Free Book "Make Real Money On The Internet"

Sunday, January 3, 2010

Becton-dickinson Posiflush Pre-filled Syringe - 10ml 5ml 10usp Heparin Fill Luer-lok Tip Syringe Only 30 Units 1 Unit

BD PosiFlush pre-filled heparin lock BD Luer-Lok flush syringe NDC 08290-0360-05 30 sp 120 ca BD PosiFlush Pre-Filled Syringes provided convenient reliable cost-effective alternatives to vial-based systems Use BD PosiFlush and strengthen your IV catheter maintenance practices Enhance Healthcare Worker SafetyCompletely eliminate needles that may still be used to fill syringes with flush solutions Eliminate glass vials and cartridges Compatible with all needleless IV access systems Improve Clinician Work Flow and ProductivityReduce clinician steps and time required to prepare flush syringes Reduce acquisition storage distribution and disposal costs for the multiple components currently required to flush IV sites Eliminate waste associated with saline and heparin vials Reduce sharps collector waste up to 1 2 compared to conventional 12mL syringes 1 Reduce Medical Errors and ComplicationsEliminate potential cross-contamination associated with multi-dose containers Minimal product manipulation provides fewer opportunities provides fewer opportunities for breaks in aseptic technique Preservative-free saline suitable for use with all patient populations BD s Pre-Filled Flush Syringes provide a fully integrated system designed to satisfy all your Flushing needs Sterile contents and fluid pathway BD PosiFlush syringes are terminally sterilized for highest SAL Saline syringes are latex free Syringes and shelf cartons are color-coded for easy identification of syringe contents10ml syringes lower injection pressures for increased patient safety 2Compatible with all needleless IV access systems Improve Clinical and Technical ProficiencyComply with PICC manufacturer instructions by standardizing flush protocols with 10 mL syringes for lower flush pressure Improve flushing proficiency with BD s Blunt Plastic Cannula 3Comply with INS Standard 56 that encourages the use of single-dose flushing systems 4 as well as with the CDC which strongly encourages use of single dose flushing systems to reduce the risk of contamination 5




  • Filling syringe - Shop sales, stores & prices at TheFind.com
    ... 5mL 0.9% Sodium Chloride, 180 Unit / Ca, Ulti Care U-100 Insulin Syringe 28 Gauge 1cc 1/2 inch Needle, Becton-Dickinson Integra, General Use Syringe - 3ml / Safety Tip ... PosiFlush, Pre-Filled Syringe - 10ml / 10ml Saline Fill / Slip Tip / Syringe Only, 30 ea Our Price: $26.52 10ml / 10ml Saline Fill / Luer-Lok ...
  • Luer lok syringe Medical Aids - PriceGrabber.com
    Glide Becton-Dickinson Precision-General Use Syringe - 3ml / Luer-Lok Tip / 25g x 1 Needle, 100 ea. 309581 . Syringes/Needle Combination3cc 25G x 1 Also available in ...
  • FDA > CDRH > MAUDE Database Search
    b-d 10ml syringe luer-lok: b-d 16g 1 1/2 needle: b-d 16g 1 1/2 ... free syringe 3ml 22 g 1-1/2: b-d latex free syringe 5ml luer-lok ... b-d luer-lok syringe 30 cc: b-d luer-lok syringe 5 ml
Claim Your Free Book "Make Real Money On The Internet"